The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

April 16, 2024

Samer A. Srour, MB ChB, MS, discusses the utility of the CAR T-cell therapy CTX130 and unmet needs in advanced clear cell renal cell carcinoma.

April 15, 2024

Núria Agustí Garcia, MD, discusses the MELISA trial, which is evaluating further steps toward lymphadenectomy replacement in ovarian cancer.

April 15, 2024

Alessandra Ferrajoli, MD, discusses the importance of shared decision-making when considering the use of BTK inhibitors in hematologic malignancies.

April 15, 2024

Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.

April 11, 2024

Shannon N. Westin, MD, MPH, FACOG, discusses the DENALI trial of azenosertib in patients with high-grade serous ovarian cancer.

April 11, 2024

Hans Lee, MD, discusses the rationale for the phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.

April 11, 2024

Michael J. Overman, MD, discusses future research directions in gastrointestinal cancers.

April 11, 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.

April 11, 2024

Phillip J. Koo, MD, discusses the clinical use of PSMA PET imaging in patients with prostate cancer.

April 09, 2024

Michael J. Overman, MD, discusses the rationale for utilizing a nonoperative management approach over traditional surgery in gastrointestinal cancers.

April 09, 2024

Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.

April 09, 2024

Samer A. Srour, MB ChB, MS, discusses efficacy and safety data for the allogeneic CAR T-cell therapy CTX130 in advanced clear cell renal cell carcinoma.

April 08, 2024

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

April 08, 2024

Adagrasib plus cetuximab elicited a 34% objective response rate in patients with previously treated KRAS G12C-mutant advanced colorectal cancer.

April 08, 2024

Dr Jabbour expands on the FDA approval of ponatinib for patients with Ph-positive ALL, the agent’s mechanism of action, and data from the PhALLCON trial.

April 08, 2024

The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.

April 08, 2024

Michael R. Migden, MD, discusses efficacy data for RP1 in advanced non-melanoma skin cancer after prior solid organ transplant.

April 05, 2024

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

April 03, 2024

Debu Tripathy, MD, discusses the current treatment paradigm of HER2-positive breast cancer and highlights unmet needs that remain.

March 29, 2024

Voruciclib plus venetoclax had antileukemic activity with acceptable safety in patients with relapsed or refractory acute myeloid leukemia.